Identification
NameBortezomib
Accession NumberDB00188  (APRD00828, DB07475)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Bortezomib (originally PS-341 and marketed as Velcade by Millennium Pharmaceuticals) is the first therapeutic proteasome inhibitor to be tested in humans. The boron atom within bortezomib catalytically binds the active site of the 26S proteasome with high affinity and specificity, thereby resulting in cell cycle arrest and apoptosis. In normal cells, the proteasome is involved in degradation of ubiquitylated proteins that have been tagged for destruction because they are damaged or unneeded by the cell. However, in cancerous cells, proteasome activity degrades pro-apoptotic proteins such as p53 that would normally result in programmed cell death of the dysfunctional cells. Proteasome inhibitors such as bortezomib interrupt this process, resulting in destruction of cancerous cells.

Bortezomib is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing disease.

Structure
Thumb
Synonyms
[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE
External IDs LDP 341 / LDP-341 / LDP341 / LDP-341 / PS 341 / PS-341 / PS341
Product Ingredients Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act BortezomibPowder, for solution3.5 mgIntravenous; SubcutaneousActavis Pharma Company2015-11-17Not applicableCanada
BortezomibPowder, for solution3.5 mgIntravenous; SubcutaneousApotex CorporationNot applicableNot applicableCanada
Bortezomib for InjectionPowder, for solution3.5 mgIntravenous; SubcutaneousSandoz Canada IncorporatedNot applicableNot applicableCanada
Bortezomib for InjectionPowder, for solution3.5 mgIntravenous; SubcutaneousTeva2015-01-06Not applicableCanada
Bortezomib for InjectionPowder, for solution3.5 mgIntravenous; SubcutaneousDr Reddy's Laboratories2017-03-21Not applicableCanada
PMS-bortezomibPowder, for solution3.5 mgIntravenous; SubcutaneousPharmascience IncNot applicableNot applicableCanada
VelcadeInjection, powder, lyophilized, for solution3.5 mg/1Intravenous; SubcutaneousMillennium Pharmaceuticals, Inc.2003-05-13Not applicableUs
VelcadePowder, for solution3.5 mgIntravenous; SubcutaneousJanssen Pharmaceuticals2005-02-01Not applicableCanada
VelcadeInjection, powder, for solution1.0 mgIntravenousJanssen Cilag International Nv2004-04-26Not applicableEu
VelcadeInjection, powder, for solution3.5 mgIntravenous; SubcutaneousJanssen Cilag International Nv2004-04-26Not applicableEu
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bortezomib AccordInjection, powder, for solution3.5 mgIntravenous; SubcutaneousAccord Healthcare Limited2015-07-20Not applicableEu
Bortezomib HospiraInjection, powder, for solution3.5 mgIntravenous; SubcutaneousHospira, Inc.2016-07-22Not applicableEu
Bortezomib SunInjection, powder, for solution3.5 mgIntravenous; SubcutaneousSun Pharmaceutical Industries (Europe) B.V.2016-07-22Not applicableEu
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNII69G8BD63PP
CAS number179324-69-7
WeightAverage: 384.237
Monoisotopic: 384.196885774
Chemical FormulaC19H25BN4O4
InChI KeyGXJABQQUPOEUTA-RDJZCZTQSA-N
InChI
InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1
IUPAC Name
[(1R)-3-methyl-1-[(2S)-3-phenyl-2-(pyrazin-2-ylformamido)propanamido]butyl]boronic acid
SMILES
CC(C)C[[email protected]](NC(=O)[[email protected]](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
Pharmacology
Indication

For treatment of multiple myeloma in patients who have not been successfully treated with at least two previous therapies.

Structured Indications
Pharmacodynamics

Bortezomib is a drug that inhibits the mammalian 26S proteasome. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostatic mechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety of cancer cell types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models, including multiple myeloma. Tumor cells, that is, rapidly dividing cells, appear to be more sensitive to proteasome inhibition.

Mechanism of action

Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The active site of the proteasome has chymotrypsin-like, trypsin-like, and postglutamyl peptide hydrolysis activity. The 26S proteasome degrades various proteins critical to cancer cell survival, such as cyclins, tumor suppressors, BCL-2, and cyclin-dependent kinase inhibitors. Inhibition of these degradations sensitizes cells to apoptosis. Bortezomib is a potent inhibitor of 26S proteasome, which sensitizes activity in dividing multiple myeloma and leukemic cells, thus inducing apoptosis. In addition, bortezomib appears to increase the sensitivity of cancer cells to traditional anticancer agents (e.g., gemcitabine, cisplatin, paclitaxel, irinotecan, and radiation).

TargetKindPharmacological actionActionsOrganismUniProt ID
Proteasome subunit beta type-5Proteinyes
inhibitor
HumanP28074 details
Proteasome subunit beta type-1Proteinyes
inhibitor
HumanP20618 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding

83% over the concentration range of 100-1000 ng/ml.

Metabolism

In vitro studies with human liver microsomes and human cDNA-expressed cytochrome P450 isozymes indicate that bortezomib is primarily oxidatively metabolized via cytochrome P450 enzymes 3A4, 2C19, and 1A2, while bortezomib metabolism by CYP 2D6 and 2C9 enzymes is minor. The major metabolic pathway is deboronation to form 2 deboronated metabolites that subsequently undergo hydroxylation to several metabolites which are inactive as 26S proteasome inhibitors.

SubstrateEnzymesProduct
Bortezomib
Bortezomib metabolite M1Details
Bortezomib
Bortezomib metabolite M2Details
Bortezomib metabolite M1
Not Available
Bortezomib metabolite M3Details
Bortezomib metabolite M2
Not Available
Bortezomib metabolite M3Details
Bortezomib metabolite M3
Not Available
Bortezomib metabolite M4Details
Bortezomib metabolite M1
Not Available
Bortezomib metabolite M5Details
Bortezomib metabolite M2
Not Available
Bortezomib metabolite M6Details
Bortezomib metabolite M2
Bortezomib metabolite M8Details
Bortezomib metabolite M8
Not Available
Bortezomib metabolite M33Details
Bortezomib
Not Available
Bortezomib metabolite M34Details
Bortezomib metabolite M1
Not Available
Bortezomib metabolite M25Details
Bortezomib metabolite M1
Not Available
Bortezomib metabolite M26Details
Bortezomib metabolite M2
Not Available
Bortezomib metabolite M27Details
Bortezomib metabolite M2
Not Available
Bortezomib metabolite M28Details
Bortezomib
Bortezomib metabolite M23 or M24 (1)Details
Bortezomib
Bortezomib metabolite M23 or M24 (2)Details
Route of elimination

The pathways of elimination of bortezomib have not been characterized in humans.

Half life

The mean elimination half-life of bortezomib after first dose ranged from 9 to 15 hours at doses ranging from 1.45 to 2.00 mg/m2 in patients with advanced malignancies.

Clearance
  • 102 L/h [patients with multiple myeloma following the first dose for doses of 1 mg/m2]
  • 112 L/h [patients with multiple myeloma following the first dose for doses of 1.3 mg/m2]
  • 15 - 32 L/h [patients with multiple myeloma following subsequent doses for doses of 1 and 1.3 mg/m2]
Toxicity

Cardiovascular safety pharmacology studies in monkeys show that lethal IV doses are associated with decreases in blood pressure, increases in heart rate, increases in contractility, and ultimately terminal hypotension. In monkeys, doses of 3.0 mg/m2 and greater (approximately twice the recommended clinical dose) resulted in progressive hypotension starting at 1 hour and progressing to death by 12 to 14 hours following drug administration.

Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Bortezomib can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Bortezomib.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Bortezomib.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Bortezomib.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Bortezomib is combined with Acetazolamide.Approved, Vet Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Bortezomib.Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Bortezomib.Approved
AgomelatineThe serum concentration of Agomelatine can be increased when it is combined with Bortezomib.Approved, Investigational
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Bortezomib.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Bortezomib.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Bortezomib.Approved
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Bortezomib.Approved, Illicit
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Bortezomib.Approved, Investigational
AliskirenThe metabolism of Aliskiren can be decreased when combined with Bortezomib.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Bortezomib.Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Bortezomib.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Bortezomib.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Bortezomib.Approved, Withdrawn
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Bortezomib.Approved, Illicit, Investigational
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Bortezomib.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Bortezomib.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Bortezomib.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Bortezomib.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Bortezomib.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Bortezomib.Approved
AmiodaroneThe serum concentration of Bortezomib can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Bortezomib.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Bortezomib.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Bortezomib.Approved, Illicit
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Bortezomib.Approved, Vet Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Bortezomib.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Bortezomib.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Bortezomib.Approved
AnagrelideBortezomib may increase the QTc-prolonging activities of Anagrelide.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Bortezomib.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Bortezomib.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Bortezomib.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Bortezomib.Approved
ApremilastThe metabolism of Apremilast can be decreased when combined with Bortezomib.Approved, Investigational
AprepitantThe serum concentration of Bortezomib can be increased when it is combined with Aprepitant.Approved, Investigational
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Bortezomib.Approved, Investigational
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Bortezomib.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Bortezomib.Approved, Investigational
ArmodafinilThe metabolism of Bortezomib can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Bortezomib.Approved
Arsenic trioxideBortezomib may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherBortezomib may increase the QTc-prolonging activities of Artemether.Approved
AsenapineBortezomib may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Bortezomib.Approved, Withdrawn
AtazanavirThe serum concentration of Bortezomib can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Bortezomib.Approved
AtomoxetineThe metabolism of Bortezomib can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Bortezomib.Approved
AV650The metabolism of AV650 can be decreased when combined with Bortezomib.Approved, Investigational
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Bortezomib.Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Bortezomib.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Bortezomib.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Bortezomib.Approved
AzithromycinBortezomib may increase the QTc-prolonging activities of Azithromycin.Approved
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Bortezomib.Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Bortezomib.Experimental
BarbitalBarbital may increase the hypotensive activities of Bortezomib.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Bortezomib.Approved
BCG vaccineThe therapeutic efficacy of Bcg can be decreased when used in combination with Bortezomib.Investigational
BedaquilineBortezomib may increase the QTc-prolonging activities of Bedaquiline.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Bortezomib.Approved, Investigational
BendamustineThe metabolism of Bendamustine can be decreased when combined with Bortezomib.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Bortezomib.Approved
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Bortezomib.Approved
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Bortezomib.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Bortezomib.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Bortezomib.Approved, Withdrawn
BetaxololThe metabolism of Betaxolol can be decreased when combined with Bortezomib.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Bortezomib.Approved, Investigational
BexaroteneThe serum concentration of Bortezomib can be decreased when it is combined with Bexarotene.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Bortezomib.Approved
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Bortezomib.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Bortezomib.Approved
BoceprevirThe serum concentration of Bortezomib can be increased when it is combined with Boceprevir.Withdrawn
BosentanThe serum concentration of Bosentan can be increased when it is combined with Bortezomib.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Bortezomib.Approved
Brentuximab vedotinThe metabolism of Brentuximab vedotin can be decreased when combined with Bortezomib.Approved
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Bortezomib.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Bortezomib.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Bortezomib.Approved
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Bortezomib.Approved
BromazepamThe metabolism of Bromazepam can be decreased when combined with Bortezomib.Approved, Illicit
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Bortezomib.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Bortezomib.Approved
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Bortezomib.Approved
BudesonideThe metabolism of Budesonide can be decreased when combined with Bortezomib.Approved
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Bortezomib.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Bortezomib.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Bortezomib.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bortezomib can be decreased when combined with Bupropion.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Bortezomib.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Bortezomib.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bortezomib.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Bortezomib.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Bortezomib.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Bortezomib.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Bortezomib.Approved, Nutraceutical
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Bortezomib.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Bortezomib.Approved
CapecitabineThe metabolism of Bortezomib can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Bortezomib.Approved
CarbamazepineThe serum concentration of Bortezomib can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Bortezomib is combined with Carbetocin.Approved
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Bortezomib.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Bortezomib.Approved
CarisoprodolThe metabolism of Carisoprodol can be decreased when combined with Bortezomib.Approved
CarmustineThe metabolism of Carmustine can be decreased when combined with Bortezomib.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Bortezomib.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Bortezomib.Approved, Investigational
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Bortezomib.Approved, Investigational
CeliprololThe metabolism of Celiprolol can be decreased when combined with Bortezomib.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Bortezomib.Approved, Vet Approved
CeritinibThe serum concentration of Bortezomib can be increased when it is combined with Ceritinib.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Bortezomib.Withdrawn
CevimelineThe metabolism of Cevimeline can be decreased when combined with Bortezomib.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Bortezomib.Approved
ChloramphenicolThe metabolism of Bortezomib can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Bortezomib.Approved, Illicit
ChloroquineBortezomib may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Bortezomib.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Bortezomib.Approved
ChlorpromazineBortezomib may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Bortezomib.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Bortezomib.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Bortezomib.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Bortezomib.Approved, Nutraceutical
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Bortezomib.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Bortezomib.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Bortezomib is combined with Cilnidipine.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Bortezomib.Approved
CimetidineThe metabolism of Bortezomib can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Bortezomib can be decreased when combined with Cinacalcet.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Bortezomib.Approved
CiprofloxacinBortezomib may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideBortezomib may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Bortezomib.Approved
ClarithromycinThe serum concentration of Bortezomib can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Bortezomib can be decreased when combined with Clemastine.Approved
ClenbuterolThe metabolism of Clenbuterol can be decreased when combined with Bortezomib.Approved, Vet Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Bortezomib.Approved
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Bortezomib.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Bortezomib.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Bortezomib is combined with Clofarabine.Approved, Investigational
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Bortezomib.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Bortezomib.Approved
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Bortezomib.Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Bortezomib.Approved, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Bortezomib.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Bortezomib.Approved
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Bortezomib resulting in a loss in efficacy.Approved, Nutraceutical
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Bortezomib.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Bortezomib.Approved, Illicit
ClotrimazoleThe metabolism of Bortezomib can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Bortezomib is combined with Clozapine.Approved
CobicistatThe serum concentration of Bortezomib can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Bortezomib.Approved
CocaineThe metabolism of Bortezomib can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe metabolism of Codeine can be decreased when combined with Bortezomib.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Bortezomib.Approved
ConivaptanThe serum concentration of Bortezomib can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Bortezomib.Approved
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Bortezomib.Approved
CrizotinibBortezomib may increase the QTc-prolonging activities of Crizotinib.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Bortezomib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Bortezomib.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Bortezomib.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Bortezomib can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CytarabineThe metabolism of Cytarabine can be decreased when combined with Bortezomib.Approved, Investigational
DabrafenibThe serum concentration of Bortezomib can be decreased when it is combined with Dabrafenib.Approved
DacarbazineThe metabolism of Dacarbazine can be decreased when combined with Bortezomib.Approved, Investigational
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Bortezomib.Approved
DantroleneThe metabolism of Dantrolene can be decreased when combined with Bortezomib.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Bortezomib.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Bortezomib.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Bortezomib.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Bortezomib.Approved, Investigational
DarunavirThe serum concentration of Bortezomib can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Bortezomib.Approved
DasatinibThe serum concentration of Bortezomib can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Bortezomib.Approved
DeferasiroxThe serum concentration of Bortezomib can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Bortezomib can be decreased when combined with Delavirdine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Bortezomib is combined with Desflurane.Approved
DesipramineThe metabolism of Desipramine can be decreased when combined with Bortezomib.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Bortezomib.Approved
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Bortezomib.Approved
DexamethasoneThe serum concentration of Bortezomib can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Bortezomib.Approved, Illicit, Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Bortezomib.Approved, Vet Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Bortezomib.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Bortezomib.Approved, Illicit, Withdrawn
DiazepamThe metabolism of Diazepam can be decreased when combined with Bortezomib.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Bortezomib.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Bortezomib.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Bortezomib.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Bortezomib.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Bortezomib.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Bortezomib.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Bortezomib.Approved
DinoprostoneThe metabolism of Dinoprostone can be decreased when combined with Bortezomib.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Bortezomib.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Bortezomib.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Bortezomib.Approved
DisopyramideBortezomib may increase the QTc-prolonging activities of Disopyramide.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Bortezomib.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bortezomib.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Bortezomib.Approved
DolasetronBortezomib may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Bortezomib.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Bortezomib.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Bortezomib.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Bortezomib.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Bortezomib.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Bortezomib.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Bortezomib.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Bortezomib.Approved, Investigational
DoxycyclineThe metabolism of Bortezomib can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Bortezomib.Approved, Illicit
DronedaroneBortezomib may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolBortezomib may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DuloxetineBortezomib may increase the orthostatic hypotensive activities of Duloxetine.Approved
DutasterideThe metabolism of Dutasteride can be decreased when combined with Bortezomib.Approved, Investigational
EfavirenzThe serum concentration of Bortezomib can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Bortezomib is combined with Efonidipine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Bortezomib.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Bortezomib.Approved
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Bortezomib.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Bortezomib.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Bortezomib.Approved
EnalaprilThe metabolism of Enalapril can be decreased when combined with Bortezomib.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Bortezomib is combined with Enalaprilat.Approved
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Bortezomib.Approved, Investigational
EnzalutamideThe serum concentration of Bortezomib can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Bortezomib.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Bortezomib.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Bortezomib is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Bortezomib.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Bortezomib.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Bortezomib.Approved
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Bortezomib.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Bortezomib.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Bortezomib.Approved, Investigational
ErythromycinBortezomib may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramBortezomib may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Bortezomib can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Bortezomib.Approved
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Bortezomib.Approved, Investigational
EstazolamThe metabolism of Estazolam can be decreased when combined with Bortezomib.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Bortezomib.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Bortezomib.Approved
EstramustineThe metabolism of Estramustine can be decreased when combined with Bortezomib.Approved
EstroneThe metabolism of Estrone can be decreased when combined with Bortezomib.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Bortezomib.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Bortezomib.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Bortezomib.Approved
EthanolThe metabolism of Ethanol can be decreased when combined with Bortezomib.Approved
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Bortezomib.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Bortezomib.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Bortezomib.Approved, Illicit
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Bortezomib.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Bortezomib.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Bortezomib.Approved, Investigational
EtravirineThe serum concentration of Bortezomib can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Bortezomib.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Bortezomib.Approved, Investigational
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Bortezomib.Approved
FamotidineThe metabolism of Famotidine can be decreased when combined with Bortezomib.Approved
FelbamateThe metabolism of Felbamate can be decreased when combined with Bortezomib.Approved
FelodipineThe metabolism of Felodipine can be decreased when combined with Bortezomib.Approved, Investigational
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Bortezomib.Approved
FenoldopamThe risk or severity of adverse effects can be increased when Bortezomib is combined with Fenoldopam.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Bortezomib.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Bortezomib.Approved
FimasartanThe risk or severity of adverse effects can be increased when Bortezomib is combined with Fimasartan.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Bortezomib.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Bortezomib.Approved, Investigational
FlecainideBortezomib may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Bortezomib.Approved
FloxuridineThe metabolism of Bortezomib can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Bortezomib can be decreased when combined with Fluconazole.Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Bortezomib.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Bortezomib.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Bortezomib.Approved, Illicit
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Bortezomib.Approved
FluorouracilThe metabolism of Bortezomib can be decreased when combined with Fluorouracil.Approved
FluoxetineBortezomib may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolBortezomib may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Bortezomib.Approved, Illicit
FlutamideThe metabolism of Flutamide can be decreased when combined with Bortezomib.Approved
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Bortezomib.Approved
Fluticasone propionateThe metabolism of Fluticasone Propionate can be decreased when combined with Bortezomib.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Bortezomib.Approved
FluvoxamineThe metabolism of Bortezomib can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Bortezomib.Approved, Investigational
FosamprenavirThe metabolism of Fosamprenavir can be decreased when combined with Bortezomib.Approved
FosaprepitantThe serum concentration of Bortezomib can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Bortezomib.Approved
FosphenytoinThe serum concentration of Bortezomib can be decreased when it is combined with Fosphenytoin.Approved
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Bortezomib.Approved, Investigational
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Bortezomib.Approved, Investigational
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Bortezomib.Approved, Vet Approved
Fusidic AcidThe serum concentration of Bortezomib can be increased when it is combined with Fusidic Acid.Approved
Gadobenic acidBortezomib may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Bortezomib.Approved
GefitinibThe metabolism of Gefitinib can be decreased when combined with Bortezomib.Approved, Investigational
GemfibrozilThe metabolism of Bortezomib can be decreased when combined with Gemfibrozil.Approved
GemifloxacinBortezomib may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GenisteinThe metabolism of Genistein can be decreased when combined with Bortezomib.Investigational
GliclazideThe metabolism of Gliclazide can be decreased when combined with Bortezomib.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Bortezomib.Approved
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Bortezomib.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Bortezomib.Approved
GoserelinBortezomib may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronBortezomib may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Bortezomib.Withdrawn
GuanabenzThe metabolism of Guanabenz can be decreased when combined with Bortezomib.Approved
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Bortezomib.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Bortezomib.Approved
HaloperidolBortezomib may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Bortezomib.Approved, Vet Approved
HesperetinThe metabolism of Hesperetin can be decreased when combined with Bortezomib.Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Bortezomib.Approved
HistamineThe metabolism of Histamine Phosphate can be decreased when combined with Bortezomib.Approved, Investigational
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Bortezomib.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Bortezomib.Approved, Vet Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Bortezomib.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Bortezomib.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Bortezomib is combined with Hydroflumethiazide.Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Bortezomib.Approved, Illicit
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Bortezomib.Approved
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Bortezomib.Approved
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Bortezomib.Approved
IbutilideBortezomib may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Bortezomib can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Bortezomib resulting in a loss in efficacy.Approved
IloperidoneBortezomib may increase the QTc-prolonging activities of Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Bortezomib is combined with Iloprost.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Bortezomib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Bortezomib is combined with Imidapril.Investigational
ImipramineThe metabolism of Imipramine can be decreased when combined with Bortezomib.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Bortezomib.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Bortezomib.Approved
IndapamideThe metabolism of Indapamide can be decreased when combined with Bortezomib.Approved
IndinavirThe serum concentration of Bortezomib can be increased when it is combined with Indinavir.Approved
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Bortezomib.Approved, Investigational
IndoraminThe risk or severity of adverse effects can be increased when Bortezomib is combined with Indoramin.Withdrawn
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Bortezomib.Approved
IrbesartanThe metabolism of Bortezomib can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Bortezomib.Approved, Investigational
IsavuconazoniumThe metabolism of Isavuconazonium can be decreased when combined with Bortezomib.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Bortezomib is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Bortezomib is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Bortezomib can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Bortezomib.Approved
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Bortezomib.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Bortezomib.Approved, Withdrawn
IsradipineThe metabolism of Isradipine can be decreased when combined with Bortezomib.Approved
ItraconazoleThe serum concentration of Bortezomib can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Bortezomib.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Bortezomib.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Bortezomib.Approved, Vet Approved
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Bortezomib.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Bortezomib.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Bortezomib.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Bortezomib.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Bortezomib.Approved
KetoconazoleThe serum concentration of Bortezomib can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Bortezomib.Approved
LacidipineThe risk or severity of adverse effects can be increased when Bortezomib is combined with Lacidipine.Approved
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Bortezomib.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Bortezomib.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Bortezomib.Investigational
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Bortezomib.Approved, Investigational
LenvatinibBortezomib may increase the QTc-prolonging activities of Lenvatinib.Approved
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Bortezomib.Approved, Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Bortezomib.Approved, Investigational
LeuprolideBortezomib may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Bortezomib.Approved
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Bortezomib.Approved
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Bortezomib.Approved
LevodopaBortezomib may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinBortezomib may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Bortezomib.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Bortezomib.Approved
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Bortezomib.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Bortezomib is combined with Levosimendan.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Bortezomib.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Bortezomib.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Bortezomib.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Bortezomib.Approved
LofexidineThe risk or severity of adverse effects can be increased when Bortezomib is combined with Lofexidine.Approved, Investigational
LomefloxacinThe metabolism of Lomefloxacin can be decreased when combined with Bortezomib.Approved
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Bortezomib.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Bortezomib.Approved
LopinavirThe serum concentration of Bortezomib can be increased when it is combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Bortezomib.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Bortezomib.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Bortezomib.Approved
LovastatinThe metabolism of Lovastatin can be decreased when combined with Bortezomib.Approved, Investigational
LuliconazoleThe serum concentration of Bortezomib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Bortezomib can be decreased when it is combined with Lumacaftor.Approved
LumefantrineBortezomib may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Bortezomib.Approved, Investigational
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Bortezomib.Approved
MacitentanThe metabolism of Macitentan can be decreased when combined with Bortezomib.Approved
MalathionThe metabolism of Malathion can be decreased when combined with Bortezomib.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Bortezomib.Approved, Investigational
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Bortezomib.Approved
MaravirocThe metabolism of Maraviroc can be decreased when combined with Bortezomib.Approved, Investigational
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Bortezomib.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Bortezomib.Approved
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Bortezomib.Approved, Investigational
MefloquineThe metabolism of Mefloquine can be decreased when combined with Bortezomib.Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Bortezomib.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Bortezomib.Approved, Vet Approved
MenadioneThe metabolism of Menadione can be decreased when combined with Bortezomib.Approved, Nutraceutical
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Bortezomib.Investigational, Withdrawn
MeprobamateThe metabolism of Meprobamate can be decreased when combined with Bortezomib.Approved, Illicit
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Bortezomib.Withdrawn
MethadoneBortezomib may increase the QTc-prolonging activities of Methadone.Approved
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Bortezomib.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Bortezomib.Approved
MethohexitalMethohexital may increase the hypotensive activities of Bortezomib.Approved
MethotrimeprazineThe metabolism of Bortezomib can be decreased when combined with Methotrimeprazine.Approved
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Bortezomib.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Bortezomib.Approved, Vet Approved
MethsuximideThe metabolism of Methsuximide can be decreased when combined with Bortezomib.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bortezomib.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Bortezomib.Approved
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Bortezomib.Approved
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Bortezomib.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Bortezomib.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Bortezomib.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Bortezomib.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Bortezomib.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Bortezomib.Approved
MexiletineThe metabolism of Bortezomib can be decreased when combined with Mexiletine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Bortezomib.Approved
MibefradilThe metabolism of Mibefradil can be decreased when combined with Bortezomib.Withdrawn
MiconazoleThe metabolism of Miconazole can be decreased when combined with Bortezomib.Approved, Investigational, Vet Approved
MidazolamThe metabolism of Midazolam can be decreased when combined with Bortezomib.Approved, Illicit
MifepristoneThe serum concentration of Bortezomib can be increased when it is combined with Mifepristone.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Bortezomib.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Bortezomib.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Bortezomib.Approved
MitotaneThe serum concentration of Bortezomib can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Bortezomib.Approved
ModafinilThe serum concentration of Bortezomib can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Bortezomib.Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Bortezomib.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Bortezomib.Approved, Investigational
MoxifloxacinBortezomib may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Bortezomib is combined with Moxonidine.Approved
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Bortezomib.Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Bortezomib.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Bortezomib is combined with Nabilone.Approved, Investigational
NabumetoneThe metabolism of Nabumetone can be decreased when combined with Bortezomib.Approved
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Bortezomib.Approved
NafcillinThe serum concentration of Bortezomib can be decreased when it is combined with Nafcillin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Bortezomib.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Bortezomib.Approved, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Bortezomib.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Bortezomib.Approved, Investigational
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Bortezomib.Approved, Investigational
NefazodoneThe serum concentration of Bortezomib can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Bortezomib can be increased when it is combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Bortezomib.Approved, Investigational
NetupitantThe serum concentration of Bortezomib can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Bortezomib can be decreased when it is combined with Nevirapine.Approved
NicardipineThe metabolism of Bortezomib can be decreased when combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Bortezomib.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Bortezomib.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Bortezomib.Approved
NilotinibBortezomib may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilutamideThe metabolism of Nilutamide can be decreased when combined with Bortezomib.Approved
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Bortezomib.Approved
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Bortezomib.Approved
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Bortezomib.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Bortezomib.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Bortezomib.Approved
Nitric OxideThe metabolism of Nitric Oxide can be decreased when combined with Bortezomib.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Bortezomib.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Bortezomib.Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Bortezomib.Approved
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Bortezomib.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Bortezomib.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Bortezomib is combined with Obinutuzumab.Approved
OfloxacinBortezomib may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Bortezomib.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Bortezomib.Approved
OleandrinAnvirzel may decrease the cardiotoxic activities of Bortezomib.Experimental
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bortezomib.Approved, Investigational
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Bortezomib.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Bortezomib.Approved, Investigational, Vet Approved
OndansetronBortezomib may increase the QTc-prolonging activities of Ondansetron.Approved
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Bortezomib.Approved
OsimertinibThe serum concentration of Bortezomib can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Bortezomib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Bortezomib.Approved
OxaliplatinThe metabolism of Oxaliplatin can be decreased when combined with Bortezomib.Approved, Investigational
OxazepamThe metabolism of Oxazepam can be decreased when combined with Bortezomib.Approved
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Bortezomib.Approved
OxprenololThe risk or severity of adverse effects can be increased when Bortezomib is combined with Oxprenolol.Approved
OxtriphyllineThe metabolism of Oxtriphylline can be decreased when combined with Bortezomib.Approved
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Bortezomib.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Bortezomib is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Bortezomib.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Bortezomib.Approved, Vet Approved
PalbociclibThe serum concentration of Bortezomib can be increased when it is combined with Palbociclib.Approved
PaliperidoneBortezomib may increase the QTc-prolonging activities of Paliperidone.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Bortezomib.Approved, Investigational
PanobinostatThe serum concentration of Bortezomib can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Bortezomib.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Bortezomib.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Bortezomib.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Bortezomib.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Bortezomib.Approved
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Bortezomib.Approved, Investigational
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Bortezomib.Approved
ParoxetineThe metabolism of Bortezomib can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibBortezomib may increase the QTc-prolonging activities of Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Bortezomib can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Bortezomib.Approved, Investigational
PentamidineBortezomib may increase the QTc-prolonging activities of Pentamidine.Approved
PentobarbitalThe serum concentration of Bortezomib can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PentoxifyllineThe metabolism of Pentoxifylline can be decreased when combined with Bortezomib.Approved, Investigational
PerampanelThe metabolism of Perampanel can be decreased when combined with Bortezomib.Approved
PerflutrenBortezomib may increase the QTc-prolonging activities of Perflutren.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Bortezomib.Approved, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Bortezomib.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Bortezomib.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Bortezomib.Approved, Investigational
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Bortezomib.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Bortezomib.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Bortezomib.Withdrawn
PhenelzineThe risk or severity of adverse effects can be increased when Bortezomib is combined with Phenelzine.Approved
PhenobarbitalThe serum concentration of Bortezomib can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Bortezomib.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Bortezomib.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Bortezomib is combined with Phentolamine.Approved
PhenytoinThe serum concentration of Bortezomib can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Bortezomib.Approved
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Bortezomib.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Bortezomib.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Bortezomib.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Bortezomib.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Bortezomib.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Bortezomib is combined with Pipamperone.Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Bortezomib.Approved
PirfenidoneThe serum concentration of Pirfenidone can be increased when it is combined with Bortezomib.Investigational
PodofiloxThe metabolism of Podofilox can be decreased when combined with Bortezomib.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Bortezomib.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Bortezomib.Approved
PosaconazoleThe serum concentration of Bortezomib can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Bortezomib is combined with Pramipexole.Approved, Investigational
PrasteroneThe metabolism of Prasterone can be decreased when combined with Bortezomib.Approved, Nutraceutical
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Bortezomib.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Bortezomib.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Bortezomib.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Bortezomib.Approved, Vet Approved
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Bortezomib.Approved
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Bortezomib.Approved, Vet Approved
PrednisoneThe metabolism of Prednisone can be decreased when combined with Bortezomib.Approved, Vet Approved
PrimaquineBortezomib may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe serum concentration of Bortezomib can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcainamideBortezomib may increase the QTc-prolonging activities of Procainamide.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Bortezomib.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Bortezomib.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Bortezomib.Approved
PromazineBortezomib may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Bortezomib.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Bortezomib.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Bortezomib.Approved, Investigational
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Bortezomib.Approved
PyrimethamineThe metabolism of Bortezomib can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Bortezomib.Approved, Illicit
QuetiapineBortezomib may increase the QTc-prolonging activities of Quetiapine.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Bortezomib.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Bortezomib.Approved, Investigational
QuinidineBortezomib may increase the QTc-prolonging activities of Quinidine.Approved
QuinineBortezomib may increase the QTc-prolonging activities of Quinine.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Bortezomib.Approved, Investigational
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Bortezomib.Approved, Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Bortezomib.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Bortezomib.Approved
RanitidineThe metabolism of Ranitidine can be decreased when combined with Bortezomib.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Bortezomib.Approved, Investigational
RasagilineThe metabolism of Rasagiline can be decreased when combined with Bortezomib.Approved
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Bortezomib.Approved, Investigational
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Bortezomib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Bortezomib is combined with Remifentanil.Approved
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Bortezomib.Approved, Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Bortezomib.Approved
ResveratrolThe metabolism of Resveratrol can be decreased when combined with Bortezomib.Experimental, Investigational
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Bortezomib.Approved
RifabutinThe serum concentration of Bortezomib can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Bortezomib can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Bortezomib can be decreased when it is combined with Rifapentine.Approved
RilpivirineThe metabolism of Rilpivirine can be decreased when combined with Bortezomib.Approved
RiluzoleThe metabolism of Riluzole can be decreased when combined with Bortezomib.Approved, Investigational
RimonabantThe metabolism of Rimonabant can be decreased when combined with Bortezomib.Approved, Investigational
RiociguatThe metabolism of Riociguat can be decreased when combined with Bortezomib.Approved
RisperidoneBortezomib may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe serum concentration of Bortezomib can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Bortezomib.Approved
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Bortezomib.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Bortezomib.Investigational, Withdrawn
RolapitantThe metabolism of Rolapitant can be decreased when combined with Bortezomib.Approved
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Bortezomib.Approved, Investigational
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Bortezomib.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Bortezomib.Approved
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Bortezomib.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Bortezomib.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Bortezomib.Approved, Withdrawn
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Bortezomib.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Bortezomib is combined with Sacubitril.Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Bortezomib.Approved
SaquinavirThe serum concentration of Bortezomib can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Bortezomib.Approved
SecobarbitalThe metabolism of Bortezomib can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Bortezomib.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Bortezomib.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Bortezomib.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Bortezomib.Approved, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Bortezomib.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Bortezomib.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Bortezomib.Approved, Illicit, Investigational, Withdrawn
SildenafilThe metabolism of Sildenafil can be decreased when combined with Bortezomib.Approved, Investigational
SilodosinThe metabolism of Silodosin can be decreased when combined with Bortezomib.Approved
SiltuximabThe serum concentration of Bortezomib can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Bortezomib.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Bortezomib.Approved
SirolimusThe metabolism of Sirolimus can be decreased when combined with Bortezomib.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Bortezomib.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Bortezomib is combined with Sodium Nitrite.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Bortezomib.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Bortezomib.Approved, Investigational
SorafenibThe metabolism of Sorafenib can be decreased when combined with Bortezomib.Approved, Investigational
SotalolBortezomib may increase the QTc-prolonging activities of Sotalol.Approved
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Bortezomib.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Bortezomib.Approved
St. John's WortThe serum concentration of Bortezomib can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Bortezomib can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Bortezomib is combined with Streptokinase.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Bortezomib.Approved, Investigational
SulfadiazineThe metabolism of Bortezomib can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Bortezomib.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Bortezomib.Approved
SulfisoxazoleThe metabolism of Bortezomib can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Bortezomib.Approved, Investigational
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Bortezomib.Approved
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Bortezomib.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Bortezomib.Approved
TacrineThe metabolism of Tacrine can be decreased when combined with Bortezomib.Withdrawn
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Bortezomib.Approved, Investigational
TadalafilThe metabolism of Tadalafil can be decreased when combined with Bortezomib.Approved, Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Bortezomib.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Bortezomib.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Bortezomib.Approved
TasosartanThe metabolism of Tasosartan can be decreased when combined with Bortezomib.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Bortezomib.Experimental
TelaprevirThe serum concentration of Bortezomib can be increased when it is combined with Telaprevir.Withdrawn
TelavancinBortezomib may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe serum concentration of Bortezomib can be increased when it is combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Bortezomib.Approved, Investigational
TemafloxacinThe metabolism of Temafloxacin can be decreased when combined with Bortezomib.Withdrawn
TemazepamThe metabolism of Temazepam can be decreased when combined with Bortezomib.Approved
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Bortezomib.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Bortezomib.Approved
Tenofovir disoproxilThe metabolism of Bortezomib can be decreased when combined with Tenofovir.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Bortezomib.Approved
TerbinafineThe metabolism of Bortezomib can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Bortezomib.Withdrawn
TeriflunomideThe serum concentration of Bortezomib can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Bortezomib.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Bortezomib.Approved, Investigational
TetrabenazineBortezomib may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Bortezomib.Approved, Vet Approved
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Bortezomib.Approved, Investigational, Withdrawn
TheobromineThe metabolism of Theobromine can be decreased when combined with Bortezomib.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Bortezomib.Approved
ThiabendazoleThe metabolism of Thiabendazole can be decreased when combined with Bortezomib.Approved, Vet Approved
ThiamylalThiamylal may increase the hypotensive activities of Bortezomib.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Bortezomib.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Bortezomib.Withdrawn
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Bortezomib.Approved
ThiothixeneThe metabolism of Thiothixene can be decreased when combined with Bortezomib.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Bortezomib.Approved
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Bortezomib.Approved
TiclopidineThe metabolism of Bortezomib can be decreased when combined with Ticlopidine.Approved
TimololThe metabolism of Timolol can be decreased when combined with Bortezomib.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Bortezomib.Approved, Investigational
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Bortezomib.Approved
TipranavirThe metabolism of Bortezomib can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Bortezomib.Approved
TocilizumabThe serum concentration of Bortezomib can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Bortezomib.Approved, Investigational
TolazolineThe risk or severity of adverse effects can be increased when Bortezomib is combined with Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Bortezomib can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Bortezomib is combined with Tolcapone.Approved, Withdrawn
TolterodineThe metabolism of Tolterodine can be decreased when combined with Bortezomib.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Bortezomib.Approved
TopiramateThe metabolism of Bortezomib can be decreased when combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Bortezomib.Approved
ToremifeneBortezomib may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Bortezomib.Approved, Investigational
TramadolThe metabolism of Tramadol can be decreased when combined with Bortezomib.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Bortezomib.Approved
TranylcypromineThe metabolism of Bortezomib can be decreased when combined with Tranylcypromine.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Bortezomib.Approved, Investigational
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Bortezomib.Approved
TrazodoneThe metabolism of Trazodone can be decreased when combined with Bortezomib.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Bortezomib.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Bortezomib.Approved, Vet Approved
TriamtereneThe metabolism of Triamterene can be decreased when combined with Bortezomib.Approved
TriazolamThe metabolism of Triazolam can be decreased when combined with Bortezomib.Approved
TrifluoperazineThe metabolism of Trifluoperazine can be decreased when combined with Bortezomib.Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Bortezomib.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Bortezomib.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Bortezomib.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Bortezomib.Withdrawn
UdenafilThe metabolism of Udenafil can be decreased when combined with Bortezomib.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Bortezomib.Approved
VadimezanThe metabolism of ASA404 can be decreased when combined with Bortezomib.Investigational
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Bortezomib.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Bortezomib.Approved, Investigational
ValsartanThe metabolism of Bortezomib can be decreased when combined with Valsartan.Approved, Investigational
VandetanibBortezomib may increase the QTc-prolonging activities of Vandetanib.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Bortezomib.Investigational
VardenafilThe metabolism of Vardenafil can be decreased when combined with Bortezomib.Approved
VemurafenibThe serum concentration of Bortezomib can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Bortezomib.Approved
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Bortezomib.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Bortezomib.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Bortezomib.Investigational
VilanterolThe metabolism of Vilanterol can be decreased when combined with Bortezomib.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Bortezomib.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Bortezomib.Approved
VincristineThe metabolism of Vincristine can be decreased when combined with Bortezomib.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Bortezomib.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Bortezomib.Approved, Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Bortezomib.Approved
Vitamin CThe therapeutic efficacy of Bortezomib can be decreased when used in combination with Vitamin C.Approved, Nutraceutical
VoriconazoleThe serum concentration of Bortezomib can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Bortezomib.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Bortezomib.Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Bortezomib.Approved, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Bortezomib.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Bortezomib.Approved
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Bortezomib.Approved, Illicit, Investigational
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Bortezomib.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Bortezomib.Approved, Investigational, Withdrawn
ZiprasidoneBortezomib may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Bortezomib.Approved, Investigational
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Bortezomib.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Bortezomib.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Bortezomib.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Bortezomib.Approved
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Bortezomib.Approved, Investigational
Food Interactions
  • Citrus fruits - Patients should avoid taking extra vitamin C (ascorbic acid) supplements and vitamin C-containing multi-vitamins during their bortezomib therapy. Ascorbic Acid may diminish the therapeutic effect of Bortezomib.
  • Green Tea - Green Tea may diminish the antineoplastic effect of Bortezomib. Avoid concurrent use of green tea extract and other green tea products during treatment with bortezomib.
References
Synthesis Reference

Raghavendracharyulu Venkata Palle, Rajasekhar Kadaboina, Veerendeer Murki, Amarendhar Manda, Nageshwar Gunda, Ramaseshagiri Rao Pulla, Mallesha Hanmanthu, Narasimha Naidu Mopidevi, Suresh Kumar Ramdoss, "BORTEZOMIB AND PROCESS FOR PRODUCING SAME." U.S. Patent US20100226597, issued September 09, 2010.

US20100226597
General References
  1. Adams J, Kauffman M: Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 2004;22(2):304-11. [PubMed:15199612 ]
  2. Bonvini P, Zorzi E, Basso G, Rosolen A: Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma. Leukemia. 2007 Apr;21(4):838-42. Epub 2007 Feb 1. [PubMed:17268529 ]
  3. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ: The proteasome as a target for cancer therapy. Clin Cancer Res. 2003 Dec 15;9(17):6316-25. [PubMed:14695130 ]
  4. Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, Agrawal S, Stec J, Schenkein D, Esseltine DL, Cavenagh JD: PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005 Jun;129(6):755-62. [PubMed:15953001 ]
  5. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999 Jun 1;59(11):2615-22. [PubMed:10363983 ]
  6. Berkers CR, Verdoes M, Lichtman E, Fiebiger E, Kessler BM, Anderson KC, Ploegh HL, Ovaa H, Galardy PJ: Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods. 2005 May;2(5):357-62. Epub 2005 Apr 21. [PubMed:15846363 ]
External Links
ATC CodesL01XX32 — Bortezomib
AHFS Codes
  • 10:00.00
PDB EntriesNot Available
FDA labelDownload (199 KB)
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingBasic ScienceMultiple Myeloma (MM)1
0CompletedTreatmentAutologous Transplant / Malignant Lymphoma, Stem Cell Type1
0CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias1
0TerminatedTreatmentLymphoma, B-Cell1
0TerminatedTreatmentMultiple Myeloma (MM)1
1Active Not RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Therapy-Related Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
1Active Not RecruitingTreatmentFallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Endometrioid Adenocarcinoma / Fallopian Tube Mucinous Adenocarcinoma / Fallopian Tube Serous Adenocarcinoma / Fallopian Tube Transitional Cell Carcinoma / Malignant Ovarian Mixed Epithelial Tumor / Ovarian Brenner Tumor / Ovarian Clear Cell Adenocarcinoma / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Adenocarcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Serous Adenocarcinoma / Ovarian Serous Cystadenocarcinoma / Ovarian Transitional Cell Carcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
1Active Not RecruitingTreatmentGraft Versus Host Disease (GVHD)1
1Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections / Kaposi's Sarcoma AIDS Related / Recurrent Kaposi's Sarcoma1
1Active Not RecruitingTreatmentLeukemias / Malignant Lymphomas1
1Active Not RecruitingTreatmentMalignancies, Hematologic1
1Active Not RecruitingTreatmentMalignant Lymphomas / Mantle Cell Lymphoma (MCL)1
1Active Not RecruitingTreatmentMantle Cell Lymphoma (MCL)1
1Active Not RecruitingTreatmentMultiple Myeloma (MM)3
1Active Not RecruitingTreatmentMultiple Myeloma in Relapse1
1Active Not RecruitingTreatmentPlasma Cell Myeloma1
1Active Not RecruitingTreatmentRecurrent Plasma Cell Myeloma1
1Active Not RecruitingTreatmentRelapsed/Refractory Multiple Myeloma1
1Active Not RecruitingTreatmentTumors, Solid / Urethral Cancer1
1CompletedBasic ScienceAdult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Multiple Myeloma / Splenic Marginal Zone Lymphoma / Stage III Multiple Myeloma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific / Waldenstrom's Macroglobulinemia (WM)1
1CompletedOtherNon-Small-Cell Lung Carcinoma (NSCLC)1
1CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myeloid Leukaemias (AML) / Chronic Myelogenous Leukemia (CML) / Myelodysplastic Syndrome1
1CompletedTreatmentAcute Myelogenous Leukaemia (AML)1
1CompletedTreatmentAcute Myeloid Leukaemias (AML) / Acute Myeloid Leukemia With Multilineage Dysplasia Following / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Myelodysplastic Syndrome / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia1
1CompletedTreatmentAdult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Megakaryoblastic Leukemia / Adult Acute Monoblastic Leukemia / Adult Acute Monocytic Leukemia / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With Maturation / Adult Acute Myeloid Leukemia With Minimal Differentiation / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Myeloid Leukemia Without Maturation / Adult Acute Myelomonocytic Leukemia / Adult Erythroleukemia / Adult Pure Erythroid Leukemia / Blastic Phase / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Disease / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia1
1CompletedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia1
1CompletedTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
1CompletedTreatmentAdult Acute Promyelocytic Leukemia (M3) / Blastic Phase Chronic Myelogenous Leukemia / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Relapsing Chronic Myelogenous Leukemia1
1CompletedTreatmentAdult Grade III Lymphomatoid Granulomatosis / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Post-Transplant Lymphoproliferative Disorder / Primary Central Nervous System Hodgkin Lymphoma / Primary Central Nervous System Non-Hodgkin Lymphoma / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Splenic Marginal Zone Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific / Waldenstrom's Macroglobulinemia (WM)1
1CompletedTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Hepatosplenic T-Cell Lymphoma / Leukemia, Prolymphocytic / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Small Intestine Lymphoma / T-Cell Large Granular Lymphocyte Leukemia1
1CompletedTreatmentAdvanced Cancer, Various, NOS1
1CompletedTreatmentAdvanced Malignancy / Malignant Lymphomas / Plasma Cell Myeloma / Tumors, Solid1
1CompletedTreatmentAdvanced or Metastatic Solid Tumors1
1CompletedTreatmentBlastic Phase Chronic Myelogenous Leukemia / Childhood Acute Promyelocytic Leukemia (M3) / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia1
1CompletedTreatmentBrain Cancer / Central Nervous System Neoplasms / Cervix Cancer / Head and Neck Carcinoma1
1CompletedTreatmentBrain and Central Nervous System Tumors / Malignant Lymphomas / Metastatic Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentBreast Cancer Metastatic1
1CompletedTreatmentCancer, Advanced2
1CompletedTreatmentCancer, Breast / Cancer, Ovarian / Colorectal Cancers / Head and Neck Carcinoma / Lung Cancers / Malignant Neoplasm of Pancreas / Melanoma (Skin) / Prostate Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentCancer, Breast / Cancer, Ovarian / Colorectal Cancers / Head and Neck Carcinoma / Lung Cancers / Malignant Neoplasm of Pancreas / Prostate Cancer / Renal Cancers / Sarcomas1
1CompletedTreatmentCancer, Breast / Colorectal Cancers / Head and Neck Carcinoma / Lung Cancers / Malignant Neoplasm of Pancreas / Renal Cancers / Sarcomas / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cancer1
1CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
1CompletedTreatmentCarcinoid Tumors / Lung Cancer Small Cell Lung Cancer (SCLC) / Melanoma / Parathyroid Carcinoma / Soft Tissue Sarcoma (STS)1
1CompletedTreatmentChildhood Burkitt Lymphoma / Childhood Central Nervous System Choriocarcinoma / Childhood Central Nervous System Germ Cell Tumor / Childhood Central Nervous System Germinoma / Childhood Central Nervous System Mixed Germ Cell Tumor / Childhood Central Nervous System Teratoma / Childhood Central Nervous System Yolk Sac Tumor / Childhood Choroid Plexus Tumor / Childhood Craniopharyngioma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Medulloepithelioma / Childhood Meningioma / Childhood Mixed Glioma / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Childhood Oligodendroglioma / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Central Nervous System Embryonal Tumor / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Malignant Germ Cell Tumor / Recurrent Childhood Medulloblastoma / Recurrent Childhood Pineoblastoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Childhood Subependymal Giant Cell Astrocytoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Childhood Visual Pathway and Hypothalamic Glioma / Recurrent Childhood Visual Pathway Glioma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Indolent Non-Hodgkin's Lymphomas / Mantle Cell Lymphoma (MCL)1
1CompletedTreatmentColorectal Cancers2
1CompletedTreatmentExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hematopoietic/Lymphoid Cancer / Nodal marginal zone B-cell lymphomas / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1CompletedTreatmentExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Nodal Marginal Zone Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Refractory Plasma Cell Myeloma / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1CompletedTreatmentGlioblastoma Multiforme1
1CompletedTreatmentGraft Versus Host Disease (GVHD) / Peripheral Blood Stem Cell Transplantation / Transplantation, Homologous1
1CompletedTreatmentHead and Neck Carcinoma1
1CompletedTreatmentHead and Neck Carcinoma / Laryngeal Cancer / Oral Cancers / Pharyngeal Cancer / Squamous Carcinoma1
1CompletedTreatmentHepatic Complications / Neoplasms, Malignant1
1CompletedTreatmentLeukemias1
1CompletedTreatmentLeukemias / Malignant Lymphomas / Mature T-cell and Nk-cell Neoplasms / Multiple Myeloma and Plasma Cell Neoplasm1
1CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
1CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Precancerous Conditions / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentLeukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
1CompletedTreatmentLung Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentLymphoma, Hodgkins / Malignant Lymphomas1
1CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1CompletedTreatmentMalignant Lymphomas2
1CompletedTreatmentMalignant Lymphomas / Neuroblastomas / Sarcomas / WilmsTumor1
1CompletedTreatmentMalignant Lymphomas / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentMalignant Pleural Effusions / Recurrent Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
1CompletedTreatmentMantle Cell Lymphoma (MCL)1
1CompletedTreatmentMelanoma2
1CompletedTreatmentMultiple Myeloma (MM)17
1CompletedTreatmentMultiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentMultiple Myeloma (MM) / Refractory Multiple Myeloma / Relapsed Multiple Myeloma1
1CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm3
1CompletedTreatmentMyelodysplasia1
1CompletedTreatmentNeuroblastomas1
1CompletedTreatmentNon-Hodgkin's Lymphoma (NHL) / Tumors1
1CompletedTreatmentProstate Cancer1
1CompletedTreatmentRefractory Chronic Lymphocytic Leukemia / Refractory Multiple Myeloma / Stage III Multiple Myeloma / Stage IV Chronic Lymphocytic Leukemia / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1CompletedTreatmentSquamous Cell Carcinoma (SCC)1
1CompletedTreatmentTumors1
1CompletedTreatmentTumors, Solid2
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific9
1CompletedTreatmentUnspecified Childhood Solid Tumor, Protocol Specific1
1RecruitingBasic ScienceSoft Tissue Sarcoma Adult1
1RecruitingOtherMultiple Myeloma (MM)1
1RecruitingPreventionHematopoetic Stem Cell Transplant1
1RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Myelodysplastic Syndrome1
1RecruitingTreatmentDysferlinopathy1
1RecruitingTreatmentHaematological Malignancies / Plasma Cell Myeloma1
1RecruitingTreatmentLeukemias1
1RecruitingTreatmentLymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)1
1RecruitingTreatmentMalignant Lymphomas / Relapsed/Refractory T-cell Lymphomas1
1RecruitingTreatmentMultiple Myeloma (MM)2
1RecruitingTreatmentNeuroblastomas1
1RecruitingTreatmentRecurrent B-Cell Non-Hodgkin Lymphoma / Recurrent Mantle Cell Lymphoma / Refractory B-Cell Non-Hodgkin Lymphoma / Refractory Mantle Cell Lymphoma1
1RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1RecruitingTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma1
1SuspendedTreatmentLight Chain Deposition Disease / Primary Systemic Amyloidosis1
1TerminatedTreatment714leukemia / Malignant Lymphomas1
1TerminatedTreatmentAdult Grade III Lymphomatoid Granulomatosis / AIDS-related Peripheral/Systemic Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific / Waldenstrom's Macroglobulinemia (WM)1
1TerminatedTreatmentAdult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1TerminatedTreatmentAdult Anaplastic Astrocytoma / Adult Anaplastic Oligodendroglioma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Tumor1
1TerminatedTreatmentAdult Non-Hodgkin's Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma1
1TerminatedTreatmentAdvanced Solid Tumors1
1TerminatedTreatmentLymphoma, B-Cell / Non-Hodgkin's Lymphoma (NHL)1
1TerminatedTreatmentLymphoproliferative Disorders / Malignant Lymphomas1
1TerminatedTreatmentMultiple Myeloma (MM)4
1TerminatedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1TerminatedTreatmentMyelodysplastic Syndrome1
1TerminatedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1TerminatedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1Unknown StatusTreatmentMultiple Myeloma (MM)1
1Unknown StatusTreatmentNon-Hodgkin's Lymphoma (NHL)1
1Unknown StatusTreatmentRefractory Autoimmune Cytopenia(s)1
1WithdrawnTreatmentMultiple Myeloma (MM)1
1WithdrawnTreatmentMultiple Myeloma (MM) / Multiple Myeloma in Relapse / Refractory Multiple Myeloma1
1WithdrawnTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1, 2Active Not RecruitingPreventionHaematological Malignancies1
1, 2Active Not RecruitingTreatmentCognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Therapy-Related Toxicity / Tiredness / Waldenstrom's Macroglobulinemia (WM)1
1, 2Active Not RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1, 2Active Not RecruitingTreatmentLeukemias / Malignant Lymphomas1
1, 2Active Not RecruitingTreatmentMalignant Lymphomas2
1, 2Active Not RecruitingTreatmentMantle Cell Lymphoma (MCL)1
1, 2Active Not RecruitingTreatmentMedullary Thyroid Cancer (MTC)1
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM)6
1, 2Active Not RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1, 2Active Not RecruitingTreatmentRefractory Multiple Myeloma1
1, 2Active Not RecruitingTreatmentRenal Cell Adenocarcinoma1
1, 2Active Not RecruitingTreatmentWaldenstrom's Macroglobulinemia (WM)1
1, 2CompletedPreventionMalignancies, Hematologic1
1, 2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1, 2CompletedTreatmentAcute Myeloid Leukaemias (AML)1
1, 2CompletedTreatmentAcute Myeloid Leukaemias (AML) / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Untreated Adult Acute Myeloid Leukemia1
1, 2CompletedTreatmentAdult T-cell lymphomas/leukaemias1
1, 2CompletedTreatmentAmyloidosis1
1, 2CompletedTreatmentCancer, Breast / Cancer, Ovarian / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentFollicular Lymphoma (FL) / Lymphoma, B-Cell1
1, 2CompletedTreatmentLung Cancers1
1, 2CompletedTreatmentLung Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentLymphoma, B-Cell / Lymphoma, Large-Cell, Diffuse1
1, 2CompletedTreatmentLymphoma, Mantle-Cell1
1, 2CompletedTreatmentMalignancies, Hematologic / Multiple Myeloma (MM)1
1, 2CompletedTreatmentMantle Cell Lymphoma (MCL)1
1, 2CompletedTreatmentMantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL)1
1, 2CompletedTreatmentMultiple Myeloma (MM)9
1, 2CompletedTreatmentMultiple Myeloma (MM) / Multiple Myeloma in Relapse1
1, 2CompletedTreatmentMultiple Myeloma (MM) / Patient Participation1
1, 2CompletedTreatmentMultiple Myeloma (MM) / Refractory / Relapses1
1, 2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm2
1, 2CompletedTreatmentMultiple Myeloma in Relapse1
1, 2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
1, 2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL) / Peripheral T-Cell Lymphoma (PTCL)1
1, 2CompletedTreatmentPlasma Cell Myeloma2
1, 2CompletedTreatmentProstatic Neoplasms1
1, 2CompletedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer1
1, 2CompletedTreatmentRefractory Acute Leukemia / Relapsed Acute Leukemia1
1, 2CompletedTreatmentRefractory Multiple Myeloma1
1, 2CompletedTreatmentRelapsed Or Refractory Multiple Myeloma1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1, 2RecruitingTreatmentAcute Myeloid Leukaemias (AML)1
1, 2RecruitingTreatmentCancer, Advanced1
1, 2RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Multiple Myeloma (MM) / Plasma Cell Myeloma1
1, 2RecruitingTreatmentKidney Transplant Rejection1
1, 2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2RecruitingTreatmentMantle Cell Lymphoma (MCL)1
1, 2RecruitingTreatmentMultiple Myeloma (MM)2
1, 2RecruitingTreatmentNeuroblastoma Recurrent1
1, 2RecruitingTreatmentTransplants and Implants1
1, 2RecruitingTreatmentTreatments1
1, 2TerminatedTreatmentBrain and Central Nervous System Tumors / Melanoma / Tumors, Solid1
1, 2TerminatedTreatmentCancers / Multiple Myeloma (MM)1
1, 2TerminatedTreatmentColorectal Cancers1
1, 2TerminatedTreatmentMalignant Lymphomas1
1, 2TerminatedTreatmentMultiple Myeloma (MM)2
1, 2TerminatedTreatmentPlasma Cell Myeloma / Plasmacytosis / Recurrent Plasma Cell Myeloma / Smoldering Plasma Cell Myeloma1
1, 2TerminatedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma2
1, 2TerminatedTreatmentRefractory Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1, 2Unknown StatusTreatmentMultiple Myeloma (MM)2
1, 2Unknown StatusTreatmentMultiple Myeloma Patients Who Candidate for Autologous Peripheral Blood Stem Cell Transplantation1
1, 2Unknown StatusTreatmentMultiple Myeloma and Plasma Cell Neoplasm2
1, 2Unknown StatusTreatmentMyelodysplastic Syndromes1
1, 2Unknown StatusTreatmentNon-Hodgkin's Lymphoma (NHL)1
1, 2Unknown StatusTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1, 2Unknown StatusTreatmentTransplantation, Renal / Uremia1
1, 2WithdrawnTreatmentLung Cancers2
1, 2WithdrawnTreatmentMultiple Myeloma (MM)1
1, 2WithdrawnTreatmentMultiple Myeloma (MM) / Refractory Multiple Myeloma1
2Active Not RecruitingPreventionChronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Follicular Lymphoma (FL) / Leukaemia, Acute / Lymphoma, B-Cell / Lymphoma, Hodgkins / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Myelodysplasia / Small Lymphocytic Lymphoma (SLL)1
2Active Not RecruitingTreatmentAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Megakaryoblastic Leukemia / Adult Acute Monoblastic Leukemia / Adult Acute Monocytic Leukemia / Adult Acute Myeloid Leukemia With Minimal Differentiation / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Myeloid Leukemia Without Maturation / Adult Erythroleukemia / Adult Pure Erythroid Leukemia / Alkylating Agent-Related Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
2Active Not RecruitingTreatmentAdult Diffuse Large B-Cell Lymphoma / B-cell Non-Hodgkin's Lymphomas / Follicular Lymphoma (FL) / Mantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL) / T-Cell Non-Hodgkin Lymphoma1
2Active Not RecruitingTreatmentAmyloidosis1
2Active Not RecruitingTreatmentB-cell Adult Acute Lymphoblastic Leukemia / Ph Positive Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / T-cell Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentBrain and Central Nervous System Tumors1
2Active Not RecruitingTreatmentChronic Graft Versus Host Disease1
2Active Not RecruitingTreatmentContiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Recurrent Mantle Cell Lymphoma / Stage I Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma1
2Active Not RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma2
2Active Not RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
2Active Not RecruitingTreatmentEpstein Barr Virus Infections / Post-transplant Lymphoproliferative Disease (PTLD) / Solid Organ Transplant / Stem Cell Transplant (Bone Marrow Transplant)1
2Active Not RecruitingTreatmentEstrogen Receptor Positive / Recurrent Breast Carcinoma / Stage III Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
2Active Not RecruitingTreatmentExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Nodal Marginal Zone Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2Active Not RecruitingTreatmentGrade 3a Follicular Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma1
2Active Not RecruitingTreatmentGraft Versus Host Disease (GVHD)1
2Active Not RecruitingTreatmentIndolent Lymphoma / Malignant Lymphomas / Mantle Cell Lymphoma (MCL) / SLL1
2Active Not RecruitingTreatmentLight Chain Deposition Disease / Primary Systemic Amyloidosis1
2Active Not RecruitingTreatmentLymphoma, Hodgkins1
2Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2Active Not RecruitingTreatmentMalignant Lymphomas2
2Active Not RecruitingTreatmentMantle Cell Lymphoma (MCL)2
2Active Not RecruitingTreatmentMultiple Myeloma (MM)15
2Active Not RecruitingTreatmentMultiple Myeloma and Plasma Cell Neoplasm / Neurotoxicity1
2Active Not RecruitingTreatmentNeuromyelitis Optica Spectrum Disorder1
2Active Not RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2Active Not RecruitingTreatmentObliterative Bronchiolitis1
2Active Not RecruitingTreatmentPlasma Cell Myeloma1
2Active Not RecruitingTreatmentRecurrent Adult Diffuse Large Cell Lymphoma / Recurrent Mantle Cell Lymphoma1
2Active Not RecruitingTreatmentRecurrent Mantle Cell Lymphoma1
2Active Not RecruitingTreatmentRefractory Cold Agglutinin Disease1
2Active Not RecruitingTreatmentRefractory Plasma Cell Myeloma1
2Active Not RecruitingTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma2
2Active Not RecruitingTreatmentWaldenstrom's Macroglobulinemia (WM)3
2CompletedPreventionMultiple Myeloma (MM)1
2CompletedTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Stage IV Pancreatic Cancer1
2CompletedTreatmentAdenocarcinoma of the Extrahepatic Bile Duct / Adenocarcinoma of the Gallbladder / Advanced Adult Primary Liver Cancer / Gastrointestinal Cancers / Localized Unresectable Adult Primary Liver Cancer / Recurrent Adult Primary Liver Cancer / Recurrent Extrahepatic Bile Duct Cancer / Recurrent Gallbladder Cancer / Unresectable Extrahepatic Bile Duct Cancer / Unresectable Gallbladder Cancer1
2CompletedTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Large Cell Lung Cancer / Malignant Pleural Effusions / Recurrent Non-small Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentAdenocarcinoma of the Lung / Bronchoalveolar Cell Lung Cancer / Non-Small-Cell Lung Carcinoma (NSCLC) / Recurrent Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Diffuse Adenocarcinoma of the Stomach / Intestinal Adenocarcinoma of the Stomach / Mixed Adenocarcinoma of the Stomach / Recurrent Gastric Cancer / Stage IIIB Gastric Cancer / Stage IIIC Gastric Cancer / Stage IV Gastric Cancer1
2CompletedTreatmentAdult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Childhood Acute Basophilic Leukemia / Childhood Acute Eosinophilic Leukemia / Childhood Acute Erythroleukemia (M6) / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Minimally Differentiated Myeloid Leukemia (M0) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myelomonocytic Leukemia (M4) / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia1
2CompletedTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Tumor1
2CompletedTreatmentAdult Lymphocyte Depletion Hodgkin Lymphoma / Adult Lymphocyte Predominant Hodgkin Lymphoma / Adult Mixed Cellularity Hodgkin Lymphoma / Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma / Adult Nodular Sclerosis Hodgkin Lymphoma / Childhood Lymphocyte Depletion Hodgkin Lymphoma / Childhood Lymphocyte Predominant Hodgkin Lymphoma / Childhood Mixed Cellularity Hodgkin Lymphoma / Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma / Childhood Nodular Sclerosis Hodgkin Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
2CompletedTreatmentAdult Lymphocyte Depletion Hodgkin Lymphoma / Adult Mixed Cellularity Hodgkin Lymphoma / Adult Nodular Sclerosis Hodgkin Lymphoma / Recurrent Adult Hodgkin's Lymphoma1
2CompletedTreatmentAdult Primary Hepatocellular Carcinoma / Advanced Adult Primary Liver Cancer / Localized Unresectable Adult Primary Liver Cancer / Recurrent Adult Primary Liver Cancer2
2CompletedTreatmentAdvanced Solid Tumors1
2CompletedTreatmentAllogeneic Stem Cell Transplantation / Refractory Autoimmune Cytopenia(s)1
2CompletedTreatmentAnaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative) / Angioimmunoblastic T-Cell Lymphoma / Enteropathy- Type T-cell Lymphoma / Extranodal NK/T-cell Lymphoma Nasal Type / Hepatosplenic T-Cell Lymphoma / Peripheral T-cell Lymphoma (Not Otherwise Specified) / Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant1
2CompletedTreatmentAntibody-mediated Rejection / Late Rejection of Renal Transplant1
2CompletedTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Lymphoblastic Lymphoma / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter1
2CompletedTreatmentBrain and Central Nervous System Tumors1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentCarcinoid tumour of the gastrointestinal tract / Islet Cell Tumor1
2CompletedTreatmentCarcinoma, Adenoid Cystic1
2CompletedTreatmentChronic Graft Versus Host Disease1
2CompletedTreatmentCiliary Body and Choroid Melanoma, Medium/Large Size / Extraocular Extension Melanoma / Iris Melanoma / Recurrent Intraocular Melanoma / Recurrent Melanoma / Stage IV Melanoma1
2CompletedTreatmentColorectal Cancers1
2CompletedTreatmentContiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Stage I Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma1
2CompletedTreatmentDuct Cell Adenocarcinoma of the Pancreas / Stage IV Pancreatic Cancer1
2CompletedTreatmentEsophageal Cancers1
2CompletedTreatmentFollicular Lymphoma (FL)2
2CompletedTreatmentFollicular Lymphoma (FL) / Lymphoma, B-Cell / Marginal Lymphoma1
2CompletedTreatmentGlioblastomas / Gliosarcoma1
2CompletedTreatmentGliomas1
2CompletedTreatmentGraft Versus Host Disease (GVHD)1
2CompletedTreatmentHead and Neck Carcinoma1
2CompletedTreatmentHodgkins Disease (HD)1
2CompletedTreatmentInsular Thyroid Cancer / Recurrent Thyroid Cancer / Stage II Follicular Thyroid Cancer / Stage II Papillary Thyroid Cancer / Stage IV Follicular Thyroid Cancer / Stage IV Papillary Thyroid Cancer1
2CompletedTreatmentLeukemia, Plasma Cell / Multiple Myeloma (MM)1
2CompletedTreatmentLeukemias3
2CompletedTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndrome1
2CompletedTreatmentLung Cancers2
2CompletedTreatmentLymphoma, B-Cell2
2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2CompletedTreatmentLymphoma, Mucosa-Associated Lymphoid Tissue1
2CompletedTreatmentLymphoplasmacytic Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentMALT Lymphoma1
2CompletedTreatmentMalignant Lymphomas12
2CompletedTreatmentMalignant Lymphomas / Mantle Cell Lymphoma (MCL)1
2CompletedTreatmentMalignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentMalignant Neoplasm of Pancreas1
2CompletedTreatmentMalignant Neoplasm of Stomach1
2CompletedTreatmentMantle Cell Lymphoma (MCL)2
2CompletedTreatmentMantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentMesothelioma, Malignant2
2CompletedTreatmentMetastatic Transitional Cell Cancer of the Renal Pelvis and Ureter / Recurrent Bladder Cancer / Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter / Recurrent Urethral Cancer / Stage III Bladder Cancer / Stage III Urethral Cancer / Stage IV Bladder Cancer / Stage IV Urethral Cancer / Transitional Cell Carcinoma of the Bladder / Ureteral Cancer1
2CompletedTreatmentMetastatic / Non-Small-Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentMultiple Myeloma (MM)45
2CompletedTreatmentMultiple Myeloma (MM) / Renal Insuficiency1
2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm6
2CompletedTreatmentMyelodysplastic Syndromes1
2CompletedTreatmentNon Hodgkin's Follicular Lymphoma1
2CompletedTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentNon-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)1
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)3
2CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC) / Recurrent Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentPrimary Peritoneal Cavity Cancer / Recurrent Ovarian Epithelial Cancer1
2CompletedTreatmentPrimary Systemic Amyloidosis1
2CompletedTreatmentProstate Cancer3
2CompletedTreatmentProstate Neoplasms1
2CompletedTreatmentRecurrent Adenoid Cystic Carcinoma of the Oral Cavity / Recurrent Salivary Gland Cancer / Salivary Gland Adenoid Cystic Carcinoma / Stage III Adenoid Cystic Carcinoma of the Oral Cavity / Stage III Salivary Gland Cancer / Stage IV Adenoid Cystic Carcinoma of the Oral Cavity / Stage IV Salivary Gland Cancer1
2CompletedTreatmentRecurrent Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
2CompletedTreatmentRecurrent Breast Cancer / Stage IV Breast Cancer1
2CompletedTreatmentRecurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma1
2CompletedTreatmentRecurrent Melanoma / Stage IV Melanoma1
2CompletedTreatmentRecurrent Nasopharyngeal Cancer / Stage IV Nasopharyngeal Cancer1
2CompletedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentRecurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Verrucous Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVA Verrucous Carcinoma of the Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVB Verrucous Carcinoma of the Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Oropharynx / Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVC Verrucous Carcinoma of the Oral Cavity / Tongue Cancer1
2CompletedTreatmentRejection, Transplant1
2CompletedTreatmentRelapsed Follicular Lymphoma1
2CompletedTreatmentRelapsed Or Refractory Multiple Myeloma1
2CompletedTreatmentRenal Cancers3
2CompletedTreatmentSarcomas1
2CompletedTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2CompletedTreatmentTransplant, Kidney / Transplantation, Kidney1
2CompletedTreatmentWaldenstrom's Macroglobulinemia (WM)2
2CompletedTreatmentWaldenstroms Macroglobulinemia1
2Enrolling by InvitationTreatmentMultiple Myeloma (MM)1
2No Longer AvailableNot AvailableMultiple Myeloma (MM)1
2Not Yet RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Burkitt Leukemia/Lymphoma / Hematopoietic/Lymphoid Cancer / Lymphoma, Lymphoblastic1
2Not Yet RecruitingTreatmentAmyloidosis / Immunoglobulin Light Chain Deposition1
2Not Yet RecruitingTreatmentImmune Thrombocytopenia1
2Not Yet RecruitingTreatmentMantle Cell Lymphoma (MCL)1
2Not Yet RecruitingTreatmentMultiple Myeloma (MM)3
2RecruitingBasic ScienceLymphoma, Large B-Cell, Diffuse (DLBCL)1
2RecruitingPreventionAgnogenic Myeloid Metaplasia / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Follicular Lymphoma (FL) / Graft Versus Host Disease (GVHD) / Leukaemia, Acute / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Marginal Zone Lymphoma / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Small Lymphocytic Lymphoma (SLL)1
2RecruitingSupportive CareMultiple Myeloma (MM)2
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia, B-Cell / Leukemia, T-Cell / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentAcute Myelogenous Leukaemia (AML)1
2RecruitingTreatmentAdult-onset Immunodeficiency1
2RecruitingTreatmentChronic Antibody-mediated Transplant Rejection1
2RecruitingTreatmentChronic Kidney Disease (CKD) / Multiple Myeloma (MM)1
2RecruitingTreatmentExtramedullary Plasmacytoma / Isolated Plasmacytoma of Bone / Light Chain Deposition Disease / Primary Systemic Amyloidosis / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2RecruitingTreatmentHHV-8 / HIV Disease / Lymphoproliferative Disorders / Malignancies1
2RecruitingTreatmentHigh-Risk Cancer / Multiple Myeloma (MM)1
2RecruitingTreatmentInterstitial Lung Disease (ILD) / Scleroderma / Sclerosis, Progressive Systemic1
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2RecruitingTreatmentMalignant Lymphomas / Neurotoxicity / Therapy-Related Toxicity1
2RecruitingTreatmentMantle Cell Lymphoma (MCL)1
2RecruitingTreatmentMultiple Myeloma (MM)15
2RecruitingTreatmentMyasthenia Gravis / Rheumatoid Arthritis / Systemic Lupus Erythematosus (SLE)1
2RecruitingTreatmentPlasma Cell Myeloma1
2RecruitingTreatmentRelapse/Refractory Multiple Myeloma1
2RecruitingTreatmentRelapsed Acute Promyelocytic Leukemia1
2TerminatedPreventionCancers / Multiple Myeloma (MM) / Plasma Cell Myeloma1
2TerminatedPreventionDisorder of Transplanted Kidney1
2TerminatedPreventionGraft Versus Host Disease (GVHD)1
2TerminatedPreventionMultiple Myeloma (MM)1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
2TerminatedTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myeloid Leukaemias (AML) / Mixed Lineage Acute Leukemia1
2TerminatedTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Promyelocytic Leukemia (M3) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Secondary Acute Myeloid Leukemia1
2TerminatedTreatmentAdenocarcinoma, Bronchiolo-Alveolar / Non-Small-Cell Lung Carcinoma (NSCLC)1
2TerminatedTreatmentCardiac Transplant / Heart Transplantation / Primary Heart Transplant1
2TerminatedTreatmentCervical Cancers1
2TerminatedTreatmentFollicular Lymphoma (FL)4
2TerminatedTreatmentHodgkins Disease (HD)1
2TerminatedTreatmentLeukemia, Lymphocytic, Chronic, B-Cell / Lymphoma, Mantle-Cell1
2TerminatedTreatmentLeukemias / Myelodysplastic Syndrome1
2TerminatedTreatmentLymphoma, B-Cell / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentLymphoma, Mantle-Cell1
2TerminatedTreatmentLymphoma, Mucosa-Associated Lymphoid Tissue1
2TerminatedTreatmentLymphoproliferative Disorders1
2TerminatedTreatmentMalignant Lymphomas3
2TerminatedTreatmentMalignant Neoplasm of Pancreas1
2TerminatedTreatmentMalignant Neoplasm of Stomach1
2TerminatedTreatmentMetastatic Breast Cancer (MBC)1
2TerminatedTreatmentMetastatic Renal Cell Carcinoma1
2TerminatedTreatmentMultiple Myeloma (MM)13
2TerminatedTreatmentNon-Hodgkin's Lymphoma (NHL)3
2TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)2
2TerminatedTreatmentRecurrent Adult Diffuse Large Cell Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma1
2TerminatedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2TerminatedTreatmentRefractory Multiple Myeloma1
2TerminatedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2TerminatedTreatmentRefractory Plasma Cell Myeloma1
2TerminatedTreatmentSmith-Magenis Syndrome1
2TerminatedTreatmentStage IIIB or IV Non-Small Cell Lung Cancer1
2TerminatedTreatmentWaldenstrom's Macroglobulinemia (WM)1
2Unknown StatusTreatmentBortezomib / Cyclophosphamide / Dexamethasone / Granulocyte Colony-Stimulating Factor / Plasma Cell Myeloma1
2Unknown StatusTreatmentEnd Stage Renal Disease (ESRD)1
2Unknown StatusTreatmentLeukemia, Plasma Cell / Multiple Myeloma (MM)1
2Unknown StatusTreatmentLymphoma, Mantle-Cell1
2Unknown StatusTreatmentMalignant Lymphomas1
2Unknown StatusTreatmentMesothelioma1
2Unknown StatusTreatmentMultiple Myeloma (MM)6
2Unknown StatusTreatmentMultiple Myeloma and Plasma Cell Neoplasm3
2Unknown StatusTreatmentNasopharyngeal Carcinoma1
2Unknown StatusTreatmentWaldenstrom's Macroglobulinemia (WM)1
2WithdrawnPreventionMultiple Myeloma (MM)1
2WithdrawnTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemias1
2WithdrawnTreatmentCancer, Ovarian1
2WithdrawnTreatmentCancers1
2WithdrawnTreatmentMalignant Lymphomas1
2WithdrawnTreatmentMultiple Myeloma (MM)3
2WithdrawnTreatmentMultiple Myeloma (MM) / Multiple Myeloma in Relapse1
2WithdrawnTreatmentMultiple Myeloma (MM) / Plasma Cell Myeloma1
2WithdrawnTreatmentNon-Hodgkin's Lymphoma (NHL)1
2WithdrawnTreatmentPlasma Cell Myeloma1
2WithdrawnTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2, 3CompletedTreatmentMultiple Myeloma (MM)2
2, 3TerminatedTreatmentMultiple Myeloma (MM)1
3Active Not RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Granulocytic Sarcoma / Leukaemia cutis / Myeloid Neoplasm / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Myeloid Neoplasm1
3Active Not RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3Active Not RecruitingTreatmentMantle Cell Lymphoma (MCL)1
3Active Not RecruitingTreatmentMultiple Myeloma (MM)9
3Active Not RecruitingTreatmentPlasma Cell Myeloma1
3Active Not RecruitingTreatmentPreviously Untreated Symptomatic Multiple Myeloma1
3CompletedNot AvailableMultiple Myeloma (MM)1
3CompletedDiagnosticMultiple Myeloma (MM)1
3CompletedTreatmentAmyloidosis1
3CompletedTreatmentLight Chain Deposition Disease / Primary Systemic Amyloidosis1
3CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
3CompletedTreatmentMultiple Myeloma (MM)22
3CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
3No Longer AvailableNot AvailableMultiple Myeloma (MM)1
3Not Yet RecruitingTreatmentAmyloidosis1
3Not Yet RecruitingTreatmentMultiple Myeloma (MM)2
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult T Acute Lymphoblastic Leukemia / Childhood T Acute Lymphoblastic Leukemia / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAuto Stem Cell Transplant / Multiple Myeloma (MM)1
3RecruitingTreatmentMultiple Myeloma (MM)8
3RecruitingTreatmentRelapsed/Refractory Multiple Myeloma1
3RecruitingTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3RecruitingTreatmentWaldenstrom's Macroglobulinemia (WM)1
3TerminatedTreatmentAL Amyloidosis1
3TerminatedTreatmentMultiple Myeloma (MM)4
3TerminatedTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3Unknown StatusTreatmentMultiple Myeloma (MM)2
3Unknown StatusTreatmentTransplantation, Kidney1
3WithdrawnTreatmentMalignant Lymphomas1
3WithdrawnTreatmentMultiple Myeloma (MM)1
4CompletedNot AvailableHematological Neoplasms / Multiple Myeloma (MM)2
4CompletedNot AvailableMultiple Myeloma (MM)7
4CompletedPreventionTransplantation, Kidney1
4CompletedTreatmentChronic Kidney Disease (CKD) / IgA Nephropathy1
4CompletedTreatmentHLA Sensitization1
4CompletedTreatmentMultiple Myeloma (MM)3
4CompletedTreatmentMultiple Myeloma in Relapse / Refractory Multiple Myeloma / Relapsed and Bortezomib Refractory Multiple Myeloma1
4RecruitingTreatmentMultiple Myeloma (MM)2
4RecruitingTreatmentPatients Awaiting a Living Kidney Donation1
4RecruitingTreatmentPompe's Disease1
4RecruitingTreatmentWaldenstrom's Macroglobulinemia (WM)1
4WithdrawnTreatmentHematuria / Nephritis, Lupus / Proteinuria1
Not AvailableActive Not RecruitingNot AvailableMultiple Myeloma (MM)1
Not AvailableActive Not RecruitingTreatmentAdult Grade III Lymphomatoid Granulomatosis / B-Cell Chronic Lymphocytic Leukemia / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Progressive Hairy Cell Leukemia, Initial Treatment / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Multiple Myeloma / Stage I Small Lymphocytic Lymphoma / Stage II Multiple Myeloma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Multiple Myeloma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Untreated Hairy Cell Leukemia / Waldenstrom's Macroglobulinemia (WM)1
Not AvailableAvailableNot AvailableMultiple Myeloma (MM)1
Not AvailableAvailableNot AvailableMultiple Myeloma (MM) / Multiple Myeloma in Relapse / Refractory Multiple Myeloma / Relapsed Multiple Myeloma1
Not AvailableCompletedNot AvailableAmyloidosis1
Not AvailableCompletedNot AvailableMultiple Myeloma (MM)1
Not AvailableCompletedTreatmentAcute Myelogenous Leukaemia (AML) / Myelodysplastic Syndromes1
Not AvailableCompletedTreatmentAmyloidosis1
Not AvailableCompletedTreatmentMultiple Myeloma (MM)1
Not AvailableTerminatedTreatmentMalignant Lymphomas1
Not AvailableTerminatedTreatmentSickle Cell Disorders / Sickle Cell-hemoglobin C Disease / Sickle Cell-β0-thalassemia1
Not AvailableUnknown StatusNot AvailableCardiotoxins / Heart Failure, Systolic / Multiple Myeloma (MM)1
Pharmacoeconomics
Manufacturers
  • Millennium pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Injection, powder, for solutionIntravenous; Subcutaneous3.5 mg
Injection, powder, for solutionIntravenous1.0 mg
Injection, powder, lyophilized, for solutionIntravenous; Subcutaneous3.5 mg/1
Powder, for solutionIntravenous; Subcutaneous3.5 mg
Prices
Unit descriptionCostUnit
Velcade 3.5 mg vial1590.0USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6083903 No1994-10-282014-10-28Us
CA2203936 No2005-04-122015-10-27Canada
US5780454 Yes1997-11-032017-11-03Us
US6958319 Yes2002-07-252022-07-25Us
US6713446 Yes2002-07-252022-07-25Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityThe solubility of bortezomib, as the monomeric boronic acid, is 3.3 to 3.8 mg/mL in a pH range of 2 to 6.5.Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0532 mg/mLALOGPS
logP0.89ALOGPS
logP1.53ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)13.04ChemAxon
pKa (Strongest Basic)-0.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area124.44 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity99.37 m3·mol-1ChemAxon
Polarizability40.48 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.6935
Blood Brain Barrier-0.6533
Caco-2 permeable-0.6576
P-glycoprotein substrateSubstrate0.5909
P-glycoprotein inhibitor INon-inhibitor0.785
P-glycoprotein inhibitor IINon-inhibitor1.0
Renal organic cation transporterNon-inhibitor0.9445
CYP450 2C9 substrateNon-substrate0.7145
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.5209
CYP450 1A2 substrateNon-inhibitor0.855
CYP450 2C9 inhibitorNon-inhibitor0.8267
CYP450 2D6 inhibitorNon-inhibitor0.9304
CYP450 2C19 inhibitorNon-inhibitor0.8108
CYP450 3A4 inhibitorNon-inhibitor0.7308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9604
Ames testNon AMES toxic0.7439
CarcinogenicityNon-carcinogens0.8064
BiodegradationNot ready biodegradable0.9943
Rat acute toxicity2.4537 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9936
hERG inhibition (predictor II)Non-inhibitor0.8593
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-qTof , PositiveNot Available
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-qTof , PositiveNot Available
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-0a4i-0035900000-122163b342b985220f63View in MoNA
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-016r-1397000000-e168634cfe7e1453d742View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylalanine and derivatives. These are compounds containing phenylalanine or a derivative thereof resulting from reaction of phenylalanine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentPhenylalanine and derivatives
Alternative ParentsN-acyl-alpha amino acids and derivatives / Alpha amino acid amides / Amphetamines and derivatives / Pyrazinecarboxamides / 2-heteroaryl carboxamides / Fatty amides / Heteroaromatic compounds / Secondary carboxylic acid amides / Boronic acids / Organic metalloid salts
SubstituentsPhenylalanine or derivatives / N-acyl-alpha amino acid or derivatives / Alpha-amino acid amide / Amphetamine or derivatives / Pyrazine carboxylic acid or derivatives / Pyrazinecarboxamide / 2-heteroaryl carboxamide / Monocyclic benzene moiety / Fatty amide / Pyrazine
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptorspyrazines, amino acid amide, L-phenylalanine derivative (CHEBI:52717 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Threonine-type endopeptidase activity
Specific Function:
The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This unit is responsible of the chymotrypsin-like activity of the proteasome and is one of the principal target of the proteasome in...
Gene Name:
PSMB5
Uniprot ID:
P28074
Uniprot Name:
Proteasome subunit beta type-5
Molecular Weight:
28480.01 Da
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Threonine-type endopeptidase activity
Specific Function:
The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity.
Gene Name:
PSMB1
Uniprot ID:
P20618
Uniprot Name:
Proteasome subunit beta type-1
Molecular Weight:
26489.09 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Uniprot Name:
Cytochrome P450 3A4
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Uniprot Name:
Cytochrome P450 2C19
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Uniprot Name:
Cytochrome P450 2D6
Molecular Weight:
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Uniprot Name:
Cytochrome P450 1A2
Molecular Weight:
58293.76 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Uniprot Name:
Cytochrome P450 2C9
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Drug created on June 13, 2005 07:24 / Updated on September 01, 2017 10:24